JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease

ACS Chemical Neuroscience

Volumn 5, Issue 10, 2014, Pages 1005-1019

  Atack, John R ^a   Shook, Brian C ^a   Rassnick, Stefanie ^a   Jackson, Paul F ^a   Rhodes, Kenneth ^a   Drinkenburg, Wilhelmus H ^a   Ahnaou, Abdallah ^a   Te Riele, Paula ^a   Langlois, Xavier ^a   Hrupka, Brian ^a   De Haes, Patrick ^a   Hendrickx, Herman ^a   Aerts, Nancy ^a   Hens, Koen ^a   Wellens, Annemie ^a   Vermeire, Jef ^a   Megens, Anton A H P ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

A2A antagonists; adenosine; dopamine; neurodegeneration; neuropharmacology; Parkinson's disease

Indexed keywords

2 AMINO 4 PHENYL 8 (PYRROLIDIN 1 YLMETHYL) 5H INDENO [1,2 D]PYRIMIDINE 5 ONE; 5 [5 AMINO 3 (4 FLUOROPHENYL)PYRAZIN 2 YL] 1 ISOPROPYLPYRIDINE 2(1H) ONE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; APOMORPHINE; DOPAMINE; HALOPERIDOL; ISTRADEFYLLINE; LEVODOPA; NORADRENALIN; OXIDOPAMINE; PYRIMIDINE DERIVATIVE; RECOMBINANT RECEPTOR; RESERPINE; UNCLASSIFIED DRUG; [2 AMINO 8 [2 (4 MORPHOLINYL)ETHOXY] 4 PHENYL 5H INDENO [1,2 D]PYRIMIDINE 5 ONE]; 2-AMINO-8-(2-(4-MORPHOLINYL)ETHOXY)-4-PHENYL-5H-INDENO(1,2-D)PYRIMIDIN-5-ONE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; INDENE DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; AVOIDANT PERSONALITY DISORDER; BINDING AFFINITY; BRAIN RADIOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EC50; EXPERIMENTAL HYPOACTIVITY; EXPERIMENTAL PARKINSONISM; HALOPERIDOL-INDUCED CATALEPSY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; NERVE LESION; NEUROPHARMACOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PROTEIN FOLDING; RAT; RECEPTOR OCCUPANCY; RESTLESSNESS; SLEEP WAKING CYCLE; TREATMENT RESPONSE; ANIMAL; BRAIN; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM; MOTOR ACTIVITY; MOUSE; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; WISTAR RAT;

ADENOSINE A1 RECEPTOR ANTAGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CHO CELLS; CRICETULUS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; INDENES; MALE; MICE; MOTOR ACTIVITY; NOREPINEPHRINE; PARKINSONIAN DISORDERS; PYRIMIDINES; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECOMBINANT PROTEINS;

EID: 84908021588     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn5001606     Document Type: Article

References (63)

1. Weintraub, D., Comella, C.-L., and Horn, S. (2008) Parkinson's disease - Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment Am. J. Managed Care 14, S40-S48
2. Weintraub, D., Comella, C.-L., and Horn, S. (2008b) Parkinson's disease - Part 2: Treatment of motor symptoms Am. J. Managed Care 14, S49-S58
3. Chaudhuri, K. R. and Schapira, A. H. (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol. 8, 464-474
4. Meissner, W.-G., Frasier, M., Gasser, T., Goetz, C.-G., Lozano, A., Piccini, P., Obeso, J.-A., Rascol, O., Schapira, A., Voon, V., Weiner, D.-M., Tison, F., and Bezard, E. (2011) Priorities in Parkinson's disease research Nat. Rev. Drug Discovery 10, 377-393
5. Olanow, C.-W., Agid, Y., Mizuno, Y., Albanese, A., Bonuccelli, U., Damier, P., De, Y.-J., Gershanik, O., Guttman, M., Grandas, F., Hallett, M., Hornykiewicz, O., Jenner, P., Katzenschlager, R., Langston, W.-J., LeWitt, P., Melamed, E., Mena, M.-A., Michel, P.-P., Mytilineou, C., Obeso, J.-A., Poewe, W., Quinn, N., Raisman-Vozari, R., Rajput, A.-H., Rascol, O., Sampaio, C., and Stocchi, F. (2004) Levodopa in the treatment of Parkinson's disease: current controversies Mov. Disord. 19, 997-1005
6. Abdel-Salam, O.-M. (2008) Drugs used to treat Parkinson's disease, present status and future directions CNS Neurol. Disord.: Drug Targets 7, 321-342
7. Blandini, F. and Armentero, M.-T. (2012) New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors Expert Opin. Invest. Drugs 21, 153-168
8. Fredholm, B.-B., IJzerman, A.-P., Jacobson, K.-A., Klotz, K.-N., and Linden, J. (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 53, 527-552
9. Fredholm, B.-B., IJzerman, A.-P., Jacobson, K.-A., Linden, J., and Muller, C.-E. (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update Pharmacol. Rev. 63, 1-34
10. Fredholm, B.-B. (2010) Adenosine receptors as drug targets Exp. Cell Res. 316, 1284-1288
11. Ferre, S., Quiroz, C., Woods, A.-S., Cunha, R., Popoli, P., Ciruela, F., Lluis, C., Franco, R., Azdad, K., and Schiffmann, S.-N. (2008) An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors Curr. Pharm. Des. 14, 1468-1474
12. Xu, K., Bastia, E., and Schwarzschild, M. (2005) Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease Pharmacol. Ther. 105, 267-310
13. Morelli, M., Carta, A. R., and Jenner, P. (2009) Adenosine A2A receptors and Parkinson's disease Handbook Exp. Pharmacol. 589-615
14. Fredholm, B.-B. and Svenningsson, P. (1998) Striatal adenosine A2A receptors - where are they? What do they do? Trends Pharmacol. Sci. 19, 46-48
15. Kase, H. (2001) New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia Biosci. Biotechnol. Biochem. 65, 1447-1457
16. Schiffmann, S.-N. and Vanderhaeghen, J.-J. (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons J. Neurosci. 13, 1080-1087
17. Fuxe, K., Marcellino, D., Genedani, S., and Agnati, L. (2007) Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's Disease Mov. Disord. 22, 1990-2017
18. Mishina, M., Ishiwata, K., Naganawa, M., Kimura, Y., Kitamura, S., Suzuki, M., Hashimoto, M., Ishibashi, K., Oda, K., Sakata, M., Hamamoto, M., Kobayashi, S., Katayama, Y., and Ishii, K. (2011) Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients PLoS One 6, e17338
19. Ramlackhansingh, A.-F., Bose, S.-K., Ahmed, I., Turkheimer, F.-E., Pavese, N., and Brooks, D.-J. (2011) Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease Neurology 76, 1811-1816
20. Schignitz, G., Kufner-Muhl, U., Ensinger, H., Lehr, E., and Kuhn, F.-L. (2013) A novel xanthine derivative for treatment of cognitive deficits Biol. Psychiatry 29, 694S
21. Flagmeyer, I., Haas, H.-L., and Stevens, D.-R. (1997) Adenosine A1 receptor-mediated depression of corticostriatal and thalamostriatal glutamatergic synaptic potentials in vitro Brain Res. 778, 178-185
22. Borycz, J., Pereira, M.-F., Melani, A., Rodrigues, R.-J., Kofalvi, A., Panlilio, L., Pedata, F., Goldberg, S.-R., Cunha, R.-A., and Ferré, S. (2007) Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments J. Neurochem. 101, 355-363
23. O'Neill, C., Nolan, B.-J., Macari, A., O'Boyle, K.-M., and O'Connor, J.-J. (2007) Adenosine A1 receptor-mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors Eur. J. Neurosci. 26, 3421-3428
24. Suzuki, F., Shimada, J., Shiozaki, S., Ichikawa, S., Ishii, A., Nakamura, J., Nonaka, H., Kobayashi, H., and Fuse, E. (1993) Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance J. Med. Chem. 36, 2508-2518
25. Pitsikas, N. and Borsini, F. (1997) The adenosine A1 receptor antagonist BIIP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat Eur. J. Pharmacol. 328, 19-22
26. Maemoto, T., Tada, M., Mihara, T., Ueyama, N., Matsuoka, H., Harada, K., Yamaji, T., Shirakawa, K., Kuroda, S., Akahane, A., Iwashita, A., Matsuoka, N., and Mutoh, S. (2004) Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors J. Pharmacol. Sci. 96, 42-52
27. Shook, B.-C., Rassnick, S., Wallace, N., Crooke, J., Ault, M., Chakravarty, D., Barbay, J.-K., Wang, A., Powell, M.-T., Leonard, K., Alford, V., Scannevin, R.-H., Carroll, K., Lampron, L., Westover, L., Lim, H.-K., Russell, R., Branum, S., Wells, K.-M., Damon, S., Youells, S., Li, X., Beauchamp, D.-A., Rhodes, K., and Jackson, P.-F. (2012) Design and characterization of optimized adenosine A(2)A/A(1) receptor antagonists for the treatment of Parkinson's disease J. Med. Chem. 55, 1402-1417
28. Park, A. and Stacy, M. (2012) Istradefylline for the treatment of Parkinson's disease Expert Opin. Pharmacother. 13, 111-114
29. Mihara, T., Mihara, K., Yarimizu, J., Mitani, Y., Matsuda, R., Yamamoto, H., Aoki, S., Akahane, A., Iwashita, A., and Matsuoka, N. (2007) Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition J. Pharmacol. Exp. Ther. 323, 708-719
30. Shook, B.-C., Rassnick, S., Osborne, M.-C., Davis, S., Westover, L., Boulet, J., Hall, D., Rupert, K.-C., Heintzelman, G.-R., Hansen, K., Chakravarty, D., Bullington, J.-L., Russell, R., Branum, S., Wells, K.-M., Damon, S., Youells, S., Li, X., Beauchamp, D.-A., Palmer, D., Reyes, M., Demarest, K., Tang, Y., Rhodes, K., and Jackson, P.-F. (2010) In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease J. Med. Chem. 53, 8104-8115
31. Lim, H.-K., Chen, J., Sensenhauser, C., Cook, K., Preston, R., Thomas, T., Shook, B., Jackson, P.-F., Rassnick, S., Rhodes, K., Gopaul, V., Salter, R., Silva, J., and Evans, D.-C. (2011) Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A(2A)/A(1) antagonist by minimizing bioactivation to an iminium ion reactive intermediate Chem. Res. Toxicol. 24, 1012-1030
32. Duty, S. and Jenner, P. (2011) Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease Br. J. Pharmacol. 164, 1357-1391
33. Davie, C. A. (2008) A review of Parkinson's disease Br. Med. Bull. 86, 109-127
34. The National Collaborating Centre for Chronic Conditions (2006) Symptomatic pharmacological therapy in Parkinson's disease. In Parkinson's disease, pp 59-100, Royal College of Physicians, London.
35. Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M. J., Mouradian, M. M., and Chase, T. N. (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson's disease Neurology 61, 293-296
36. Kanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K., Nakamura, J., Kase, H., Kuwana, Y., and Jenner, P. (1998) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann. Neurol. 43, 507-513
37. Stasi, M. A., Borsini, F., Varani, K., Vincenzi, F., Di Cesare, M. A., Minetti, P., Ghirardi, O., and Carminati, P. (2006) ST 1535: A preferential A2A adenosine receptor antagonist Int. J. Neuropsychopharmacol. 9, 575-584
38. Riccioni, T., Leonardi, F., and Borsini, F. (2010) Adenosine A(2A) Receptor Binding Profile of Two Antagonists, ST1535 and KW6002: Consideration on the Presence of Atypical Adenosine A(2A) Binding Sites Front. Psychiatry 1, 22
39. Park, A. and Stacy, M. (2012) Istradefylline for the treatment of Parkinson's disease Expert Opin. Pharmacother. 13, 111-114
40. Fenu, S., Pinna, A., Ongini, E., and Morelli, M. (1997) Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats Eur. J. Pharmacol. 321, 143-147
41. Hodgson, R. A., Bertorelli, R., Varty, G. B., Lachowicz, J. E., Forlani, A., Fredduzzi, S., Cohen-Williams, M. E., Higgins, G. A., Impagnatiello, F., Nicolussi, E., Parra, L. E., Foster, C., Zhai, Y., Neustadt, B. R., Stamford, A. W., Parker, E. M., Reggiani, A., and Hunter, J. C. (2009) Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e ][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression J. Pharmacol. Exp. Ther. 330, 294-303
42. Poucher, S. M., Keddie, J. R., Singh, P., Stoggall, S. M., Caulkett, P. W., Jones, G., and Coll, M. G. (1995) The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist Br. J. Pharmacol. 115, 1096-1102
43. Gillespie, R. J., Bamford, S. J., Botting, R., Comer, M., Denny, S., Gaur, S., Griffin, M., Jordan, A. M., Knight, A. R., Lerpiniere, J., Leonardi, S., Lightowler, S., McAteer, S., Merrett, A., Misra, A., Padfield, A., Reece, M., Saadi, M., Selwood, D. L., Stratton, G. C., Surry, D., Todd, R., Tong, X., Ruston, V., Upton, R., and Weiss, S. M. (2009) Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines J. Med. Chem. 52, 33-47
44. Pinna, A., Wardas, J., Simola, N., and Morelli, M. (2005) New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists Life Sci. 77, 3259-3267
45. Stone, G. A., Jarvis, M. A., Sills, M. A., Weeks, B., Snowhill, E. W., and Williams, M. (1988) Species differences in high-affinity adenosine A2 binding sites in striatal membranes from mammalian brain Drug Dev. Res. 31-46
46. Salamone, J. D., Farrar, A. M., Font, L., Patel, V., Schlar, D. E., Nunes, E. J., Collins, L. E., and Sager, T. N. (2009) Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism Behav. Brain Res. 201, 216-222
47. Justinova, Z., Ferré, S., Segal, P. N., Antoniou, K., Solinas, M., Pappas, L. A., Highkin, J. L., Hockemeyer, J., Munzar, P., and Goldberg, S. R. (2003) Involvement of adenosine A1 and A2A receptors in the adenosinergic modulation of the discriminative-stimulus effects of cocaine and methamphetamine in rats J. Pharmacol. Exp. Ther. 307, 977-986
48. O'Neill, C. E., LeTendre, M. L., and Bachtell, R. K. (2012) Adenosine A2A receptors in the nucleus accumbens bi-directionally alter cocaine seeking in rats Neuropsychopharmacology 37, 1245-1256
49. Filip, M., Zaniewska, M., Frankowska, M., Wydra, K., and Fuxe, K. (2012) The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction Curr. Med. Chem. 19, 317-355
50. Porkka-Heiskanen, T. and Kalinchuk, A. V. (2011) Adenosine, energy metabolism and sleep homeostasis Sleep Med. Rev. 15, 123-135
51. Huang, Z. L., Urade, Y., and Hayaishi, O. (2011) The role of adenosine in the regulation of sleep Curr. Top. Med. Chem. 11, 1047-1057
52. Huang, Z. L., Qu, W. M., Eguchi, N., Chen, J. F., Schwarzschild, M. A., Fredholm, B. B., Urade, Y., and Hayaishi, O. (2005) Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine Nat. Neurosci. 8, 858-859
53. Lazarus, M., Shen, H. Y., Cherasse, Y., Qu, W. M., Huang, Z. L., Bass, C. E., Winsky-Sommerer, R., Semba, K., Fredholm, B. B., Boison, D., Hayaishi, O., Urade, Y., and Chen, J. F. (2011) Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens J. Neurosci. 31, 10067-10075
54. Normile, H. J. and Barraco, R. A. (1991) N6-cyclopentyladenosine impairs passive avoidance retention by selective action at A1 receptors Brain Res. Bull. 27, 101-104
55. Brooks, D. J., Doder, M., Osman, S., Luthra, S. K., Hirani, E., Hume, S., Kase, H., Kilborn, J., Martindill, S., and Mori, A. (2008) Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain Synapse 62, 671-681
56. Hickey, P. and Stacy, M. (2012) Adenosine A2A antagonists in Parkinson's disease: what's next? Curr. Neurol. Neurosci. Rep. 12, 376-385
57. Vallano, A., Fernandez-Duenas, V., Pedros, C., Arnau, J. M., and Ciruela, F. (2011) An update on adenosine A2A receptors as drug target in Parkinson's disease CNS Neurol Disord.: Drug Targets 10, 659-669
58. El Yacoubi, M., Ledent, C., Parmentier, M., Ongini, E., Costentin, J., and Vaugeois, J.-M. (2001) In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261 Eur. J. Neurosci. 14, 1567-1570
59. Bisserbe, J. C., Pascal, O., Deckert, J., and Maziere, B. (1992) Potential use of DPCPX as probe for in vivo localization of brain A1 adenosine receptors Brain Res. 599, 6-12
60. Gregory, K. J., Herman, E. J., Ramsey, A. J., Hammond, A. S., Byun, N. E., Stauffer, S. R., Manka, J. T., Jadhav, S., Bridges, T. M., Weaver, C. D., Niswender, C. M., Steckler, T., Drinkenburg, W. H., Ahnaou, A., Lavreysen, H., Macdonald, G. J., Bartolome, J. M., Mackie, C., Hrupka, B. J., Caron, M. G., Daigle, T. L., Lindsley, C. W., Conn, P. J., and Jones, C. K. (2013) N-Aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement J. Pharmacol. Exp. Ther. 347, 438-457
61. Ahnaou, A., Dautzenberg, F. M., Geys, H., Imogai, H., Gibelin, A., Moechars, D., Steckler, T., and Drinkenburg, W. H. (2009) Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture Eur. J. Pharmacol. 603, 62-72
62. Meert, T. F., De Haes, P., and Janssen, P. A. (1989) Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats Psychopharmacology (Berlin, Ger.) 97, 206-212
63. Lewi, P. J., Niemegeers, C. J. E., and Gypen, L. M. J. (1977) First hand estimation of the median effective dose (ED50) and its confidence interval, assuming a linear log dose-response function. Internal Report N123705/1, Department of Global Medical and Scientific Information, Johnson & Johnson Pharmaceutical Research and Development, a Division of Janssen Pharmaceutica, Turnhoutseweg 30, B-2340 Beerse, Belgium.